Karyopharm Therapeutics Stock Price History
| KPTI Stock | USD 1.09 0.04 3.54% |
Below is the normalized historical share price chart for Karyopharm Therapeutics extending back to November 06, 2013. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Karyopharm Therapeutics stands at 1.09, as last reported on the 24th of April, with the highest price reaching 1.17 and the lowest price hitting 1.08 during the day.
If you're considering investing in Karyopharm Stock, it is important to understand the factors that can impact its price. Karyopharm Therapeutics appears to be dangerous, given 3 months investment horizon. Karyopharm Therapeutics has Sharpe Ratio of 0.0798, which conveys that the firm had a 0.0798% return per unit of risk over the last 3 months. By analyzing Karyopharm Therapeutics' technical indicators, you can evaluate if the expected return of 0.72% is justified by implied risk. Please exercise Karyopharm Therapeutics' Mean Deviation of 6.57, risk adjusted performance of 0.0823, and Downside Deviation of 6.47 to check out if our risk estimates are consistent with your expectations.
As of now, Karyopharm Therapeutics' Common Stock Shares Outstanding is increasing as compared to previous years. The Karyopharm Therapeutics' current Common Stock Total Equity is estimated to increase to about 14.5 K, while Total Stockholder Equity is forecasted to increase to (129.4 M). . The Karyopharm Therapeutics' current Price Earnings To Growth Ratio is estimated to increase to 0.02, while Price To Sales Ratio is projected to decrease to 0.64. Karyopharm Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 6th of November 2013 | 200 Day MA 1.1896 | 50 Day MA 1.3346 | Beta 0.056 |
Karyopharm |
Sharpe Ratio = 0.0798
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | KPTI | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 8.97 actual daily | 79 79% of assets are less volatile |
Expected Return
| 0.72 actual daily | 14 86% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 6 94% of assets perform better |
Based on monthly moving average Karyopharm Therapeutics is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Karyopharm Therapeutics by adding it to a well-diversified portfolio.
Price Book 12.0484 | Enterprise Value Ebitda (1.06) | Price Sales 0.9613 | Shares Float 105.2 M | Wall Street Target Price 5.57 |
Karyopharm Therapeutics Stock Price History Chart
There are several ways to analyze Karyopharm Stock price data. The simplest method is using a basic Karyopharm candlestick price chart, which shows Karyopharm Therapeutics price history and the buying and selling dynamics of a specified period. Many traders also use subjective judgment to their trading calls, avoiding the need to trade based on technical analysis.
| Highest Price | February 6, 2024 | 1.66 |
| Lowest Price | January 31, 2024 | 0.75 |
Karyopharm Therapeutics April 24, 2024 Stock Price Synopsis
Various analyses of Karyopharm Therapeutics' daily price changes, such as its Balance Of Power or Price Action, are crucial when deciding whether to buy, hold, or sell Karyopharm Stock. It can be used to describe the percentage change in the price of Karyopharm Therapeutics from one trading day to the next and could be a valuable metric for traders and investors to gauge the volatility and momentum of Karyopharm Stock.| Karyopharm Therapeutics Price Action Indicator | (0.05) | |
| Karyopharm Therapeutics Accumulation Distribution | 122,392 | |
| Karyopharm Therapeutics Price Daily Balance Of Power | (0.44) | |
| Karyopharm Therapeutics Price Rate Of Daily Change | 0.96 |
Karyopharm Therapeutics April 24, 2024 Stock Price Analysis
Karyopharm Stock Price History Data
The price series of Karyopharm Therapeutics for the period between Thu, Jan 25, 2024 and Wed, Apr 24, 2024 has a statistical range of 0.94 with a coefficient of variation of 17.89. The daily prices for the period are spread out with arithmetic mean of 1.26. The median price for the last 90 days is 1.33.| Open | High | Low | Close | Volume | ||
| 04/23/2024 | 1.12 | 1.17 | 1.08 | 1.09 | 1,591,093 | |
| 04/22/2024 | 1.17 | 1.20 | 1.12 | 1.13 | 791,015 | |
| 04/19/2024 | 1.26 | 1.31 | 1.13 | 1.17 | 1,440,778 | |
| 04/18/2024 | 1.42 | 1.42 | 1.22 | 1.28 | 1,306,160 | |
| 04/17/2024 | 1.19 | 1.38 | 1.14 | 1.38 | 3,175,612 | |
| 04/16/2024 | 1.14 | 1.20 | 1.03 | 1.10 | 1,171,346 | |
| 04/15/2024 | 1.22 | 1.23 | 1.14 | 1.16 | 810,682 | |
| 04/12/2024 | 1.34 | 1.35 | 1.18 | 1.22 | 1,392,195 | |
| 04/11/2024 | 1.28 | 1.34 | 1.26 | 1.34 | 680,488 | |
| 04/10/2024 | 1.31 | 1.34 | 1.25 | 1.27 | 988,363 | |
| 04/09/2024 | 1.33 | 1.41 | 1.31 | 1.34 | 709,129 | |
| 04/08/2024 | 1.38 | 1.39 | 1.29 | 1.35 | 808,885 | |
| 04/05/2024 | 1.31 | 1.41 | 1.28 | 1.36 | 751,476 | |
| 04/04/2024 | 1.29 | 1.44 | 1.25 | 1.33 | 1,490,076 | |
| 04/03/2024 | 1.39 | 1.39 | 1.28 | 1.29 | 1,121,437 | |
| 04/02/2024 | 1.55 | 1.56 | 1.38 | 1.40 | 1,070,714 | |
| 04/01/2024 | 1.51 | 1.65 | 1.45 | 1.58 | 1,473,254 | |
| 03/28/2024 | 1.45 | 1.60 | 1.43 | 1.51 | 1,266,332 | |
| 03/27/2024 | 1.41 | 1.51 | 1.37 | 1.48 | 1,301,235 | |
| 03/26/2024 | 1.40 | 1.43 | 1.38 | 1.39 | 543,979 | |
| 03/25/2024 | 1.40 | 1.45 | 1.36 | 1.39 | 581,642 | |
| 03/22/2024 | 1.44 | 1.44 | 1.34 | 1.39 | 792,754 | |
| 03/21/2024 | 1.39 | 1.47 | 1.38 | 1.42 | 652,860 | |
| 03/20/2024 | 1.39 | 1.42 | 1.32 | 1.40 | 767,420 | |
| 03/19/2024 | 1.45 | 1.50 | 1.35 | 1.37 | 949,724 | |
| 03/18/2024 | 1.52 | 1.62 | 1.45 | 1.47 | 1,371,767 | |
| 03/15/2024 | 1.41 | 1.55 | 1.34 | 1.51 | 1,725,398 | |
| 03/14/2024 | 1.42 | 1.45 | 1.32 | 1.34 | 891,235 | |
| 03/13/2024 | 1.45 | 1.53 | 1.40 | 1.42 | 738,115 | |
| 03/12/2024 | 1.48 | 1.58 | 1.41 | 1.45 | 1,019,331 | |
| 03/11/2024 | 1.58 | 1.64 | 1.47 | 1.48 | 979,873 | |
| 03/08/2024 | 1.53 | 1.70 | 1.52 | 1.57 | 2,128,528 | |
| 03/07/2024 | 1.36 | 1.61 | 1.31 | 1.53 | 3,138,674 | |
| 03/06/2024 | 1.25 | 1.40 | 1.25 | 1.33 | 1,216,358 | |
| 03/05/2024 | 1.32 | 1.34 | 1.24 | 1.25 | 1,077,662 | |
| 03/04/2024 | 1.20 | 1.32 | 1.15 | 1.31 | 1,587,106 | |
| 03/01/2024 | 1.19 | 1.27 | 1.13 | 1.19 | 1,701,364 | |
| 02/29/2024 | 1.33 | 1.36 | 1.11 | 1.16 | 3,009,098 | |
| 02/28/2024 | 1.41 | 1.44 | 1.27 | 1.33 | 1,555,652 | |
| 02/27/2024 | 1.34 | 1.42 | 1.30 | 1.41 | 1,812,095 | |
| 02/26/2024 | 1.24 | 1.37 | 1.22 | 1.31 | 1,824,095 | |
| 02/23/2024 | 1.12 | 1.31 | 1.10 | 1.24 | 1,543,813 | |
| 02/22/2024 | 1.22 | 1.25 | 1.08 | 1.13 | 1,576,852 | |
| 02/21/2024 | 1.19 | 1.23 | 1.16 | 1.21 | 1,349,119 | |
| 02/20/2024 | 1.22 | 1.27 | 1.19 | 1.21 | 1,545,630 | |
| 02/16/2024 | 1.32 | 1.38 | 1.27 | 1.27 | 1,381,854 | |
| 02/15/2024 | 1.38 | 1.40 | 1.26 | 1.30 | 1,488,877 | |
| 02/14/2024 | 1.28 | 1.48 | 1.28 | 1.36 | 2,450,926 | |
| 02/13/2024 | 1.26 | 1.33 | 1.15 | 1.29 | 2,760,448 | |
| 02/12/2024 | 1.35 | 1.43 | 1.19 | 1.30 | 2,801,675 | |
| 02/09/2024 | 1.50 | 1.56 | 1.25 | 1.34 | 2,096,242 | |
| 02/08/2024 | 1.48 | 1.61 | 1.43 | 1.51 | 2,586,292 | |
| 02/07/2024 | 1.69 | 1.69 | 1.42 | 1.53 | 2,868,686 | |
| 02/06/2024 | 1.42 | 1.95 | 1.12 | 1.66 | 15,372,562 | |
| 02/05/2024 | 1.09 | 1.45 | 1.08 | 1.35 | 8,876,742 | |
| 02/02/2024 | 0.91 | 1.08 | 0.86 | 1.04 | 2,890,418 | |
| 02/01/2024 | 0.81 | 0.92 | 0.77 | 0.90 | 1,662,402 | |
| 01/31/2024 | 0.87 | 0.92 | 0.75 | 0.75 | 2,099,554 | |
| 01/30/2024 | 0.90 | 0.90 | 0.85 | 0.87 | 538,822 | |
| 01/29/2024 | 0.91 | 0.92 | 0.87 | 0.91 | 766,392 | |
| 01/26/2024 | 0.89 | 0.94 | 0.85 | 0.91 | 816,094 |
About Karyopharm Therapeutics Stock history
Karyopharm Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Karyopharm is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Karyopharm Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Karyopharm Therapeutics stock prices may prove useful in developing a viable investing in Karyopharm Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 114.2 M | 119.9 M | |
| Net Loss | -148.8 M | -156.2 M |
Karyopharm Therapeutics Quarterly Net Working Capital |
|
Karyopharm Therapeutics Stock Technical Analysis
Karyopharm Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Did you try this?
Run Portfolio Volatility Now
Portfolio VolatilityCheck portfolio volatility and analyze historical return density to properly model market risk |
| All Next | Launch Module |
Karyopharm Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Karyopharm Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Karyopharm Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Karyopharm to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0823 | |||
| Jensen Alpha | 0.7646 | |||
| Total Risk Alpha | (0.1) | |||
| Sortino Ratio | 0.1471 | |||
| Treynor Ratio | 0.3059 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Complementary Tools for Karyopharm Stock analysis
When running Karyopharm Therapeutics' price analysis, check to measure Karyopharm Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Karyopharm Therapeutics is operating at the current time. Most of Karyopharm Therapeutics' value examination focuses on studying past and present price action to predict the probability of Karyopharm Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Karyopharm Therapeutics' price. Additionally, you may evaluate how the addition of Karyopharm Therapeutics to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |
Is Karyopharm Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeutics. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.25) | Revenue Per Share 1.279 | Quarterly Revenue Growth 0.005 | Return On Assets (0.27) | Return On Equity (8.91) |
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Karyopharm Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Karyopharm Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.